




INVITRO-CONNECT Update on non-animal test methods

Promising skin sensitisation test methods emerge

The EU animal testing ban for cosmetic ingredients triggered large-scale research activities aimed at developing non-animal test methods. This was especially true for the endpoint skin sensitisation. As a result, the biological mechanisms leading to skin sensitisation were described using the concept of Adverse Outcome Pathways (AOP) (OECD, ENV/JM/MONO(2012)10/PART1). Equally important, many promising test methods have emerged to populate the AOP key events. For example, methods like the direct peptide reactivity assay (DPRA) and the KeratinoSens™ have been formally validated and are poised for international acceptance. The OECD is currently developing test guidelines for both.

In vitro test methods addressing key events 1-3 of the OECD AOP for skin sensitisation



Regulation on skin sensitisation hazard assessment

Since the testing ban on skin sensitisation went into force in March 2013, the cosmetic industry has urgently needed a non-animal solution to continue innovating new cosmetic ingredients. Given the 2018 REACH deadline, the chemical industry still faces a tremendous challenge: skin sensitisation information is required at the lowest tonnage level, i.e. ≥ 1 ton/year. At present, the local lymph node assay is the primary option for obtaining this information, but requires at least 20 mice per test and takes about 2-3 months. The availability of non-animal test methods would eliminate another endpoint, for which the last resort in many cases is still animal testing.



INVITRO-CONNECT provides innovative solutions for non-animal testing

Even now, we can offer these industries the most advanced non-animal skin sensitisation test methods and thereby fulfil an unmet need. The prevailing view in the scientific community is that no single method will be sufficient. That is just one reason why the INVITRO-CONNECT team keeps itself up-to-date on developments in predictive and readily applicable test method combinations, i.e. testing strategies. With our wealth of knowledge, we will help you find the perfect strategy to meet your individual needs.

Our outlook – your expectations

We are convinced that the non-animal test methods available today allow us to identify the potential skin sensitisation hazard of chemicals. We expect soon, but definitively in time for the 2018 REACH deadline, that the subcategorisation of skin sensitizers required by the Classification, Labelling and Packaging (CLP) Regulation can also be accomplished without animal testing.

Let us share our solutions with you!

**Questions? Please contact our in vitro expert
Dr. Sebastian Hoffmann.**

INVITRO-CONNECT GmbH is your partner for:

- Testing and assays at over 60 accredited test laboratories
- Project management and study monitoring
- In vitro analyses and tests
- In-vitro concepts for efficient product development
- Complete Outsourcing Service including Regulatory Service for

REACH • Pharma • Biocides • Cosmetics • Medical Devices

Contact information

INVITRO-CONNECT GmbH
Pascal Piller, Managing director

Kalabinth 37
CH-9042 Speicher
Switzerland

Phone/CH: +41 33 533 23 30

Phone/D: +49 307 469 999 8
Fax/D: +49 321 213 813 37

E-Mail: contact@invitro-connect.com

www.invitro-connect.com

